If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...

(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of ... suboptimal response to autologous stem cell transplant. The Cambridge, Mass., company said it expects the move ...

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Since cutting the ribbon on its inaugural commercial-scale Smart Factory in Bridgewater earlier this year, the San ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Bristol-Myers Squibb Co’s Profitability and Valuation Ratios Bristol-Myers Squibb Co’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 17.58% ...

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Bristol Myers Squibb has signed a lease for just under 50,000 square ... feet on George Road in a suburban office complex ...